Physician profile
Sidney Newman
NPI 1235222860
$1,522.31
in general payments reported to CMS, 2019-2025
20 companies · $449 in 2025
The $449 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2021: $65.61 · 2022: $60.67 · 2023: $429 · 2024: $199 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $266.57 | 2023-2024 | Otezla |
| Abbvie INC. | $260.44 | 2024-2025 | |
| Dermavant Sciences, INC. | $166.02 | 2023 | Vtama |
| Prugen, INC. Pharmaceuticals | $138.35 | 2019 | |
| Celgene Corporation | $123.17 | 2019 | |
| Leo Pharma INC. | $101.59 | 2025 | Anzupgo, Adbry |
| E.R. Squibb & Sons, L.L.C. | $98.59 | 2023-2024 | Sotyktu |
| Genzyme Corporation | $60.67 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.70 | 2021-2023 | Siliq, Targretin |
| Janssen Biotech, INC. | $38.42 | 2023 | Tremfya |
| Organon LLC | $36.14 | 2025 | Vtama |
| Ucb, INC. | $25.37 | 2021 | |
| Botanix Sb INC | $24.53 | 2025 | Sofdra |
| Incyte Corporation | $23.17 | 2025 | Opzelura |
| Smith+Nephew, INC. | $22.39 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $19.95 | 2025 | Klisyri |
| Mayne Pharma Commercial LLC | $19.81 | 2019 | |
| Integra Lifesciences Corporation | $19.62 | 2019 | |
| Pfizer INC. | $18.47 | 2019 | |
| Galderma Laboratories, L.P. | $16.34 | 2025 | Aklief |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.